This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

More Good News from MMG

"Medical Marketing Int'l Group PLC
22 April 2005


FOR IMMEDIATE RELEASE 22nd APRIL 2005


MMI TO BE GRANTED
FURTHER US AND EUROPEAN PATENTS FOR ANTI CANCER THERAPY

Significantly strengthens patent position for Ruthenium

Medical Marketing International Group plc ('MMI') (AIM: MMG), the Cambridge,
UK-based pharmaceutical company focussed on the development of therapies for
cancer and infectious diseases, announces that it has been formally notified of
allowance of claims for two further patents by the US Patent Office and the
European Patent Office for its ruthenium-based anti-cancer therapy, being
developed by MMI's wholly-owned cancer therapy subsidiary Oncosense. These two
patents will be granted, following payment of standard fees.

These two further patents significantly strengthen MMI's protection for its
whole ruthenium library of compounds and importantly give further protection to
the Company's lead compounds that will enter into clinical development in 2005.

Commenting on today's news, David Best, Chairman of MMI Group said: 'Receiving
notifications of grant of two significant patents in the two biggest markets is
extremely good news for MMI. The new USA and EU patents, when combined with
those granted in these territories last year enhance our library of ruthenium
cancer therapies and also provide solid patent protection for our lead ruthenium
compounds.


"Commercially, it is also extremely important news. Potential marketing partners
are primarily interested in a strong patent portfolio and good clinical data.
Today's news will strengthen our negotiating position.'

As announced earlier this week, MMI will be hosting its first R&D Day on Tuesday
26th April 2005. Further details on its ruthenium portfolio together with
Genvax, its DNA cancer vaccine platform and other key developments will be given
at this time.


For further information, please contact:

David Best - Executive Chairman
MMI Group "

Baza

great news.

Great - now lets shake out these shorters and hope EK & freinds get their fingers burnt. All those who kept the faith will get their rewards.

Pumben:

No mention in Shares mag yesterday and nothing in todays IC...not unusual by any means.

Mitzy,, i agree you would think with the ups and downs of MMG over the last months there would have been mention,, any reason why not ??..JB..

Mitzy

Thanks. Excellent news this morning. The newsflow this week has been great, hopefully all coming to boil & lets hope EK is boiled at the same time.

Companies like this need all the support they can get when it is working on products which are for the good of the human race !!!

Its amazing jimmy how little coverage MMI gets apart from an article in IC back in January when they said it could be worth 600p in 12 months time.I suppose that they will hit 600p in the future.
Meanwhile its trying to break out of the 160- 200p trading range.

Killiks give a mention:
http://www.killikmorningnote.co.uk/

Will let you know what Evil as to say when huis friday diary comes out.

cheers GF.

I believe he will say very little about MMG.

Your right nothing on MMG,thats a sign that hes getting worried.

cheers GF.

Or he's out of it.

I saw from his psots on advfn that he went long for a while and had banked some cash, that was quite a few days ago.

I read between the lines that he would close his short.

Of course he leaves his phone number all over the place, so it will be easy for soemone to confirm.

All gone extremely quiet on here considering the optimism for this week!!
Lets hope that the good news see's this recover back to 300p.
Excellent posts from gf and Mitzy again last week.

Yes it could be a big week ahead, I see Mike Walters late friday had something to say on his site, Looks good.....................


Patent Power
22/4/2005

Medical Marketing has added more value by winning new patents.
[Read more

cheers Gf.

For those who have not received an invite for the R&D presentation you can follow proceedings via a live web cast which includes slides at the following address:

http://mediaserve.buchanan.uk.com

The link for MMI should appear next Tuesday.


http://mediaserve.buchanan.uk.com

cheers GF.

Hi GF.
I think you mean tomorrow, Tuesday 26th.
Cheers.

Sorry yes I do. Cheers Porky.

Seems to be a big line of sells, any adverse news out?

looked again GF, you are really right because next tuesday is tomorrow.
At first glance it looked like you had made a mistake.
Sorry for jumping the gun.
Noticed the sales but the bid price has just risen.
Hope everthing goes as expected.
Cheers.

Ah yes buyers coming back in, coming back in strongly, NICE.

cheers GF.

From the other place. The meeting is at 11.30 for 11.45

BennytheBall - 25 Apr'05 - 08:57 - 5217 of 5217


In relation to valuation, I wonder if we've lost sight of an important aspect of MMG's business model.

Have a look at slide 4 of the presentation from the last AGM, here: http://www.bendavidson.co.uk/mmg.ppt

It shows the way phase II clinical trials add the greatest value of any stage within the development pipeline. The text that goes with that slide (see the link to 'chairman's report' above) is:
"If MMI is able to license on its blockbusters at the end of stage II, shareholders should not have to wait until products are actually marketed to see a highly significant value-added step."

The implication, I've always understood, is that MMG wants to concentrate on getting drugs to this stage and then passing on the risk in a way that maximises shareholder value; i.e. selling a suite of successful phase II ruthenium products, maybe via a sale of Oncosense as a whole to a big pharma, is more in keeping with the business plan than taking each of the drugs through to market itself.

If I am right, the length of time to market and to the growth of large revenue streams from the drugs is not critical. It's the number of possible blockbusters in the portfolio and the extent to which they can be taken comprehensively through phase II trials, in a market where big pharma have a paucity of products coming through themselves, that is the most significant clue to likey market capitalisation going forward.

That might also explain the perceived delay in Ruthenium announcements - the fact that more products than expected appear to be optimum candidates for phase II trials could well mean that MMI are aiming at a cluster of trials starting at the same time to optimise the value when the big pharma waiting in the wings start bidding to buy the lot...

MS